The Opdivo from Bristol-Myers Squibb Co. - PD-1 blocker reshapes melanoma therapy

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-27, 02:08. Details in the imprint.

The Opdivo vial from Bristol-Myers Squibb Co. sits cold in the infusion fridge, a clear liquid that oncologists now reach for almost as routinely as saline. When the nurse hangs the bag, patients feel a quiet mix of hope and fatigue in the chair. The drug has turned immunotherapy from an experiment into a standard option in melanoma and other cancers.

What Opdivo is used for

Opdivo is the brand name for nivolumab, a monoclonal antibody that targets the PD-1 receptor on T-cells to release an immune brake. It is approved in many markets for advanced melanoma, non-small cell lung cancer, renal cell carcinoma and several other solid tumors. According to Bristol-Myers Squibb, the drug is indicated alone or in combination regimens depending on tumor type and line of therapy.

In advanced melanoma, Opdivo can be given as monotherapy or in combination with another checkpoint inhibitor, often ipilimumab, to deepen response rates at the cost of higher immune-related toxicity. Oncologist Dr. Steven O’Day describes the combination as a tool that can deliver durable remissions in a subset of patients who previously had few options. In non-small cell lung cancer, Opdivo is usually reserved for second-line settings after platinum-based chemotherapy, especially in tumors expressing PD-L1.

How treatment feels in practice

For the patient in the chair, Opdivo usually arrives as a 30-to-60-minute infusion every few weeks, depending on the dosing schedule the oncologist chooses. The room is quiet; the beeping pump and the cool sensation in the arm are the main reminders that something powerful is entering the bloodstream. Many patients are surprised that the infusion itself often feels uneventful compared with chemotherapy, with no immediate burning or metallic taste.

Side effects are another story and tend to show up later, as the immune system begins to turn more aggressively against normal tissues as well as the tumor. Dermatologist-oncologist Dr. Anna Pavlick notes that rash, colitis, thyroid dysfunction and hepatitis are among the more frequent immune-related adverse events with PD-1 blockade. The art of using Opdivo, she says, is catching those toxicities early, treating them with steroids when needed, and deciding whether the patient is gaining enough tumor control to justify continuing.

Dosing, schedules and combinations

Opdivo is typically dosed on a weight-based or fixed-schedule regimen, with common options including 240 mg every two weeks or 480 mg every four weeks for adults. The choice of regimen can depend on tumor type, line of therapy and logistical considerations like clinic capacity and patient travel distances. In some protocols, Opdivo is combined with chemotherapy or targeted agents to try to exploit synergy between immune activation and cytotoxic killing.

In melanoma, one of the headline combinations remains Opdivo plus the CTLA-4 blocker ipilimumab, which Bristol-Myers Squibb also markets under the brand name Yervoy. This regimen has pushed long-term survival curves upward in pivotal trials but demands close monitoring due to elevated rates of serious immune-related events. In lung cancer, Opdivo has been studied with platinum doublets and with cabozantinib and other agents, although market dynamics now include heavy competition from newer PD-1 and PD-L1 inhibitors from rival companies.

Where Opdivo stands in oncology

Opdivo helped establish the checkpoint inhibitor class as a central pillar of modern oncology, particularly in solid tumors that respond poorly to traditional chemotherapy. When Bristol-Myers Squibb first won approval for nivolumab in melanoma and lung cancer, CEO Giovanni Caforio framed the drug as a flagship in what he called a transformational immuno-oncology portfolio. Since then, rival agents such as pembrolizumab have challenged Opdivo’s market share, especially in first-line lung cancer.

Even so, Opdivo remains embedded in treatment guidelines for multiple indications and continues to generate significant revenue. For institutional buyers, the drug is a line item that hospitals negotiate in bulk contracts, often linked with other BMS products and risk-sharing arrangements. Payers focus closely on trial data that support each indication, and in some health systems they tie reimbursement to biomarkers like PD-L1 expression or tumor mutational burden to target use more precisely.

Context and Bristol-Myers Squibb shares

Opdivo sits alongside Eliquis, Yervoy and a slate of newer oncology agents as part of Bristol-Myers Squibb’s transition from its older blockbuster portfolio into a more diversified mix of immunology and targeted therapies. Net-net, the Bristol-Myers Squibb share price (ISIN US1078421011) trades on the New York Stock Exchange in US dollars, with immuno-oncology medicines like Opdivo remaining closely watched by healthcare investors.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.